Erik Digman Wiklund has been named chief executive of Targovax ASA which is developing therapies for difficult-to-treat solid tumours. He has been chief business officer and chief financial officer of the company since 2017. Prior to this, he was head of product innovation at Aker Biomarine Antarctic ASA. Dr Wiklund replaces Øystein Soug who will act as a special advisor to the company.
Targovax announced the appointment on 20 October 2021.
Copyright 2021 Evernow Publishing Ltd